Please be advised that as a precautionary measure to slow the spread of the Coronavirus (COVID-19) within our community as advised by our state and local government officials, effective Friday, March 20, 2020, our IKS Team will begin working remotely for an indefinite period. We have equipped our team with laptops, full remote file access, case management software, and all needed online tools to create, collaborate, and get work done for our clients. Please direct communication to us thru our detailed voice mail system at (402) 391-4000, emails to gmueller@inserra.com, clkkelley@inserra.com or rsewell@inserra.com, or by fax to 402-391-4039, and our Team will continue to promptly address any needs or questions that you have for us! We will let you know when we are able to move back into our office, and stay safe and home if you can until we see you in person once again.
Thanks, Craig and Ryan
Medtronic Recalls MiniMed Insulin Pumps After Many Injuries and One Death
/in Blog, News /by Mikala HardenMedtronic is recalling over 322,000 if its insulin pumps because of a missing or faulty component that can lead to over or under delivery of insulin. This can cause hypoglycemia or hyperglycemia in diabetics. The FDA has initiated a Class I Recall which means there may be significant or immediate danger of death or other serious injury from the product being recalled.
There have been over 26,000 complaints about the devices malfunctioning and one confirmed death. Over 2,175 injuries to diabetics that have used the MiniMed pump have occurred since the recall.
The recalled products are:
Consumers who have questions about this recall should call the 24-hour Medtronic hotline at 800-646-4633.
If you or a loved one has suffered from symptoms and/or injuries from using the Medtronic MiniMed insulin pumps, please call the experts at Inserra Kelley Sewell to see whether you might be entitled to compensation.
Infant Deaths Have Fisher-Price Recalling Nearly 5 Million Rock’n Play Sleepers
/in Blog, News /by Mikala HardenFisher-Price is recalling all models of Rock’n Play Sleepers after 32 infant fatalities occurred while using the product. The fatalities occurred between 2011 and 2018 “after the infants rolled over while unrestrained, or under other circumstances,” according to the (CPSC) Consumer Product Safety Commission.
The cloth-covered cradle became a staple in many households for sleep-deprived parents as it vibrated, played music and positioned the baby at an incline.
It is alleged that Fisher- Price and the CPSC knew about the deaths and danger of this product for years and could have taken steps to prevent this tragedy from happening.
Fisher-Price is offering full cash refunds for Rock’n Plays purchased in the last six months. Sleepers bought before that are eligible for a cash voucher toward a new Fisher-Price product.
If your infant has suffered from injuries from a Fisher-Price Rock’n Play Sleeper, please call the experts at Inserra Kelley Sewell to see whether you might be entitled to compensation.
NHTSA Launches Battery Investigation in Tesla Automobiles
/in Blog, News /by Mikala HardenThe National Highway Traffic Safety Administration wrote a letter to Tesla last week, saying it is investigating fires in Model S and Model X cars built from 2012 to 2019. The investigation will involve certain battery management system software updates. Tesla has until November 29, 2019, to respond to the NHTSA or it could face civil penalties up to $22,329 a day, up to a maximum of $111,642,265.
On several occasions, Tesla batteries caught fire for no apparent reason. The fires occurred both in parked and moving vehicles. Various reliable sources have indicated that Tesla should have recalled over 2,000 of their defective vehicles.
NTHSA encourages the public to contact the agency with safety concerns relating to Tesla Model S or Model X vehicles by calling 888-327-4236.
If you or a loved one has been injured in an accident involving a Tesla with a defective battery, please call the experts at Inserra Kelley Sewell to see whether you might be entitled to compensation.
Truvada Medication May Be Causing Kidney Failure and Bone Injuries
/in Blog, News /by Mikala HardenTruvada is an antiretroviral drug that that is prescribed for patients that have have a high risk of developing HIV. The medication does not cure HIV or AIDS. It was intended to help improve the patients’ quality of life.
Many persons have been harmed by Truvada by suffering from broken bones and/or kidney failure while taking the medication.
Gilead Sciences, Inc., is the maker of Truvada and the company is now being sued by hundreds of people suffering from the side effects of taking the medication. It has been reported that Gilead knew since the year 2000 that there was a safer alternative drug that they could have marketed called TAF. Despite early indicators that TAF offered a safer alternative, Gilead officials chose not to pursue development of the drug; critics say the company held the drug until it was strategically advantageous to release it. By delaying the development of the TAF by a decade, Gilead extended its patent and market dominance until 2032.
If you or a loved one suffered from osteoporosis, brittle or broken bones, or kidney failure by taking Truvada, please call the experts at Inserra Kelley Sewell to see whether you might be entitled to compensation.
Zantac Heartburn Medication Contains Cancer Carcinogens
/in Blog, News /by Mikala HardenOn September 30, 2019, the FDA announced that ranitidine (Zantac), a heartburn medication used by millions of Americans, may cause cancer. Zantac has been found to contain a carcinogenic chemical 26,000 times the FDA-approved limit. When one 150 mg tablet is ingested, it undergoes a chemical reaction in the stomach to create more than 3,100 times the FDA-approved limit of N-nitrosodimethylamine (NDMA), a chemical which the FDA, EPA and World Health Organization classify as a dangerous carcinogen.
A newly filed class-action lawsuit accuses Sanofi, the maker of Zantac, of intentionally concealing risks of taking the medication to avoid sales and profit losses. Zantac was first sold in starting in1983, and three years later it became the first drug to total $1 billion in annual sales. The Plaintiffs in the class-action lawsuit are from all over the United States, and many of them took Zantac daily for years.
On October 1, 2019, Walgreens and CVS Pharmacies suspended sales of Zantac and removed the product from their store shelves.
INSERRA l KELLEY l SEWELL wants you and yours to know that if you are taking Zantac, please consult with your physician to find out if you should immediately start taking an alternative medication.
If you or a loved one suffered from severe side effects or cancer from Zantac, please call the great mass tort Team at Inserra Kelley Sewell to see whether you might be entitled to compensation.